Cleveland Clinic | Strategic Alliance Partners

May 10, 2023

Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.

May 04, 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

May 04, 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

May 03, 2023

Shilpa Gupta, MD, discusses findings from a long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

April 28, 2023

First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.

April 27, 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

April 27, 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

April 26, 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

April 26, 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

April 20, 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

April 20, 2023

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

April 19, 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

April 19, 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

April 13, 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

April 13, 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

April 12, 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

April 12, 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

April 06, 2023

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

April 06, 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

April 06, 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.